OakChart

Atyr Pharma Inc

ATYRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

6.77-0.79 (-10.45%)
2026-11-12 00:43 CET
Market cap
18.54 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-53.32 USD m
Free cash flow, TTM
-43.86 USD m
EPS diluted, TTM
-21.74
P/E
-
Compare

Price

ATYR against its 20, 50 and 200-day averages
2050200beatmissearnings
20.0040.0060.001.6M3.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ATYRclose 6.7720-day 6.4250-day 10.87200-day 23.326.7752w high

84.8% under the 52-week high of 44.40 on 19 Feb 2026. 52-week low 4.07 on 27 Oct 2026. Last 15 sessions, 96.2% high to low

Volume 0.44× normal · the line is the 50-bar volume average

Profile

ATYR
52-week range, 7% of the way up
4.0744.40

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Employees58
IPOMay 07, 2015
Beta0.96
ATR, 14d1.06
Rel volume0.44
Inst own29.99%

Snapshot

6 groups

Valuation

Index-
Market Cap16.60M
Enterprise Value-21.42M
Income-53.32M
Sales0.00M
Book/sh13.53
Cash/sh19.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPOMay 07, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.50
P/C0.34
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.05
Current Ratio3.05
Debt/Eq0.32
LT Debt/Eq0.28
Option/ShortNo / Yes

Earnings

EPS (ttm)-21.74
EPS next Y-12.18
EPS next Q-6.01
EPS this Y37.13%
EPS next Y39.46%
EPS next 5Y25.66%
EPS past 3/5Y20.65% 14.76%
Sales past 3/5Y-73.65% -55.14%
EPS Y/Y TTM34.89%
Sales Y/Y TTM-100.00%
EPS Q/Q29.87%
Sales Q/Q-100.00%
EarningsNov 05 AMC
EPS/Sales Surpr.-18.19% -

Ownership

Insider Own-
Insider Trans-
Inst Own29.99%
Inst Trans-
ROA-64.07%
ROE-93.37%
ROIC-122.49%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA205.50%
SMA50-37.73%
SMA200-70.96%
Trades-

Technical

Shs Outstand2.51M
Shs Float-
Short Float-
Short Ratio2.74
Short Interest0.29M
52W High44.40 -84.75%
52W Low4.07 66.42%
Volatility20.93% 15.54%
ATR (14)1.06
RSI (14)41.27
Beta0.96
Rel Volume0.44
Avg Volume107.22K
Volume46,915

Performance

Perf Week9.55%
Perf Month-15.84%
Perf Quarter-69.39%
Perf Half Y-57.25%
Perf YTD-78.39%
Perf Year-78.50%
Perf 3Y-84.89%
Perf 5Y-98.04%
Perf 10Y-99.62%
Recom2.43
Target Price15.00
Prev Close7.56
Price6.77
Change %-10.45%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 16, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$1.50-77.8%
Sep 15, 2025DowngradeWWells FargoOverweight → Equal Weight$1-85.2%
Sep 15, 2025DowngradeLLeerink PartnersOutperform → Market Perform$1-85.2%
Sep 15, 2025DowngradeHH.C. WainwrightBuy → Neutral
Sep 15, 2025DowngradeCCantor FitzgeraldOverweight → Neutral
Feb 18, 2025InitiatedLLeerink PartnersOutperform$16+136.3%
Jan 06, 2025InitiatedCCantor FitzgeraldOverweight
Oct 04, 2024InitiatedWWells FargoOverweight$17+151.1%
Sep 05, 2024InitiatedJJefferiesBuy$9+32.9%
Jul 05, 2023DowngradeOOppenheimerOutperform → Perform

Peers

Mkt cap
TickerCompanyMkt cap
TVRDTvardi Therapeutics Inc17.88M
PLRXPliant Therapeutics Inc48.15M
SVRASavara Inc1.10B
ROIVRoivant Sciences Ltd30.32B
GOSSGossamer Bio Inc71.44M
INSMInsmed Inc26.49B
KYTXKyverna Therapeutics Inc316.63M
UTHRUnited Therapeutics Corp25.37B
LQDALiquidia Corp4.94B
CPIXCumberland Pharmaceuticals Inc91.70M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SCHIMMEL PAULDirectorMay 27 '26Buy0.50100,00049,630779,143May 28 04:12 PM
Shukla SanjayPresident and CEOFeb 04 '26Sale0.983,7453,655153,553Feb 04 07:17 PM
Broadfoot Jill MarieChief Financial OfficerFeb 04 '26Sale0.981,5581,52137,296Feb 04 07:15 PM
DENYES NANCYGeneral CounselFeb 04 '26Sale0.981,1181,09133,124Feb 04 07:12 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100
  • aTyr Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.45%
  • Atyr Pharma: Q3 Earnings Snapshot (Associated Press) +5.31%
  • aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update (GlobeNewswire)
  • aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine (GlobeNewswire)
  • aTyr Pharma Announces One-for-40 Reverse Stock Split (GlobeNewswire) -19.17%
  • aTyr Pharma Announces Research Collaboration with Montefiore Einstein (GlobeNewswire)
  • aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry (GlobeNewswire) -6.38%
  • aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis (InvestorsHub) -10.02%
  • aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire)
  • aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) -10.38%
  • Atyr Pharma: Q2 Earnings Snapshot (Associated Press)
  • aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD (GlobeNewswire)
  • aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 (GlobeNewswire) +9.94%
  • What It Means To Hold Moderna Stock In A Crash (Trefis) -7.40%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-7.430-6.287-7.4300.000.003
2026Q22026-08-07-4.400-4.857-4.2050.000.007
2026Q12026-05-15-4.400-5.300-4.4020.000.008
2025Q42026-03-05-5.600-7.352-5.6980.000.048
2025Q32025-11-06-10.400-7.344-10.5990.190.0011
2025Q22025-08-07-8.800-7.380-8.6690.000.0011
2025Q12025-05-07-6.800-7.640-6.8820.000.0010
2024Q42025-03-13-7.200-9.024-7.2370.000.029
2024Q32024-11-07-9.200-8.800-9.1080.000.027
2024Q22024-08-13-9.200-10.132-9.0230.000.063
2024Q12024-05-02-9.200-10.000-9.3770.240.044
2023Q42024-03-14-10.000-9.520-9.9630.003.425
2023Q32023-11-09-8.000-9.040-7.8360.351.505
2023Q22023-08-09-8.800-11.144-8.9500.000.617
2023Q12023-05-09-11.600-14.000-11.4100.002.365
2022Q42023-03-09-10.400-19.200-10.33210.390.367

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-281.2-198-281.360.420.43
2020FY-70.800-86.668-70.84510.468.53
2021FY-70.800-71.732-70.7890.002.16
2022FY-64.000-72.800-63.81210.390.36
2023FY-37.600-37.360-37.5990.350.42
2024FY-34.400-36.436-34.4850.240.21
2025FY-32.000-33.300-30.0000.190.15
2026FY--20.118--0.00
2027FY--12.180--0.00
2028FY--13.145--2.90
2029FY--16.877--31.47
2030FY--9.257--86.36

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-065000.000.000.00
2026Q4S2026-08-105000.000.000.00
2026Q4S2026-06-145000.000.000.00
2026Q4S2026-05-206000.000.000.00
2026Q4S2026-05-156010.000.000.00
2026Q4S2026-03-066010.000.000.00
2026Q4S2026-02-022009.740.0019.49
2026Q4S2025-12-2110019.4919.4919.49
2026Q4S2025-11-1230018.500.0036.00
2026Q4S2025-11-1140113.870.0036.00
2026Q4S2025-11-1040113.870.0036.00
2026Q4S2025-11-0940113.870.0036.00
2026Q4S2025-11-0840113.870.0036.00
2026Q4S2025-11-0740113.870.0036.00

Estimate history

EPS, annual-1047.2-645.204-281.356-70.845-70.789-63.812-37.599-34.485-31.884-21.7388
Period201720182019202020212022202320242025TTM
EPS, quarterly-9.108-7.237-6.882-8.669-10.599-5.698-4.402-4.205-7.433
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000.42210.455010.3860.3530.2350.190
Period201720182019202020212022202320242025TTM
Sales, quarterly00000.190000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0530.0550.0970.2750.6950.7371.5822.1012.4512.512
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.8952.1012.2252.3222.452.4512.4512.4522.512
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.190.230.3510.390.0010.460.420.00
Cost of Goods Sold Incl. D&A3.191.551.542.741.701.30--0.75
Gross Profit-3.19-1.36-1.30-2.398.69-1.30---0.75
Selling, General and Administrative Excl. Other52.7176.2666.6152.5355.0932.7125.1022.0332.07
Research and Development35.4060.2254.3742.2942.8123.2617.2914.0520.39
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-55.91-77.63-67.91-54.92-46.40-34.02-15.91-22.98-32.82
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-53.32-74.12-64.02-50.40-45.34-33.78-16.23-23.76-34.52
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-53.32-74.12-64.02-50.40-45.34-33.78-16.23-23.76-34.52
Net Income From Continuing Operations-53.32-74.12-64.02-50.39-45.34-33.77-16.22-23.60-34.52
Net Income-53.32-74.12-64.02-50.39-45.34-33.77-16.22-23.60-34.52
EPS (Recurring)-21.71-31.88-34.49-37.60-63.81-70.79-70.85-281.36-645.20
EPS (Basic, Before Extraordinaries)-21.74-31.88-34.49-37.60-63.81-70.79-70.85-281.36-645.20
EPS (Diluted)-21.74-31.88-34.49-37.60-63.81-70.79-70.85-281.36-645.20
EBITDA-52.71-76.07-66.37-52.18-44.71-32.71-14.64-21.61-32.07
Non-Operating Income (Expense)2.583.503.894.521.060.24-0.32-0.79-1.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.255.002.992.602.151.611.471.783.43
Price To Sales Ratio-383.251,143.94214.125.99-3.4033.16-
Gross Margin--717.37-555.32-676.4983.68----
Operating Margin--40,856.32-28,899.57-15,557.79-446.79--152.19-5,445.02-
Net Margin--39,009.47-27,243.83-14,274.50-436.53--155.18-5,593.13-
Shares Outstanding2.512.452.101.580.740.690.280.100.05
Market Capitalization18.5418.54304.2282.5763.53207.6142.7516.2315.16

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.190.000.000.00
Cost of Goods Sold Incl. D&A2.000.410.390.390.390.390.380.17
Gross Profit-2.00-0.41-0.39-0.39-0.20-0.39-0.38-0.17
Selling, General and Administrative Excl. Other16.7910.4811.0414.4026.5519.9315.3915.64
Research and Development10.456.757.3210.8922.1315.3811.8112.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.79-10.88-11.44-14.80-26.75-20.31-15.77-15.82
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-18.26-10.31-10.79-13.96-25.75-19.53-14.88-14.97
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.26-10.31-10.79-13.96-25.75-19.53-14.88-14.97
Net Income From Continuing Operations-18.26-10.31-10.79-13.96-25.74-19.53-14.88-14.97
Net Income-18.26-10.31-10.79-13.96-25.74-19.53-14.88-14.97
EPS (Recurring)-7.43-4.20-4.40-5.70-10.60-8.67-6.88-7.24
EPS (Basic, Before Extraordinaries)-7.43-4.20-4.40-5.70-10.60-8.67-6.88-7.24
EPS (Diluted)-7.43-4.20-4.40-5.70-10.60-8.67-6.88-7.24
EBITDA-16.79-10.48-11.04-14.40-26.36-19.93-15.39-15.64
Non-Operating Income (Expense)0.540.570.640.831.000.780.890.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.591.151.311.211.311.301.180.77
Price To Sales Ratio-308.04402.50403.96368.88--1,274.31
Gross Margin-----104.74---
Operating Margin-----14,076.32---
Net Margin-----13,549.47---
Shares Outstanding2.512.452.452.452.452.322.232.10
Market Capitalization18.5458.5476.4876.7770.69470.86268.79304.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments78.6972.1298.1766.15107.9131.6931.1449.5585.12
Short Term Receivables0.871.742.4411.780.432.040.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.688.092.392.955.221.800.781.261.87
Total Current Assets80.2481.95102.9980.87113.5735.5331.9350.8086.98
Net Property, Plant & Equipment10.3811.8614.0511.561.812.984.091.852.28
Total Investments and Advances2.232.953.483.170.000.000.000.000.00
Deferred Tax Assets1.161.221.41------
Other Assets0.150.070.130.190.160.210.170.090.09
Total Assets94.1698.05122.0795.79115.5438.7336.1952.7589.36
Short Term Debt Incl. Current Port. of LT Debt1.471.251.330.890.980.869.497.775.01
Accounts Payable3.894.323.533.111.031.430.851.042.28
Other Current Liabilities9.799.3911.569.864.003.572.582.033.10
Total Current Liabilities15.1514.9716.4213.866.015.8612.9210.8310.39
Long Term Debt10.5712.0313.7710.640.401.382.248.2614.72
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.161.221.41------
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities26.8828.2231.6024.506.417.2415.1619.1025.11
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity67.4870.0290.6671.46109.3031.6521.1833.6564.24
Total Shareholders Equity67.4870.0290.6671.46109.3031.6521.1933.6564.25
Accumulated Minority Interest-0.19-0.19-0.19-0.18-0.17-0.17-0.160.000.00
Total Equity67.2969.8390.4771.28109.1331.4821.0333.6564.25
Total Liabilities & Stockholders Equity94.1698.05122.0795.79115.5438.7336.1952.7589.36
Book Value Per Share27.5333.3357.3096.91157.31114.89217.73616.201,207.69
Tangible Book Value Per Share27.5333.3357.3096.91157.31114.89217.73616.201,207.69
Full-Time Employees585959705343444265
Price to Book Ratio0.564.340.840.821.901.350.770.451.44
Return on Assets-77.12-58.17-46.26-42.91-43.78-43.31-53.08-48.58-56.75
Return on Equity-107.81-79.69-62.16-50.16-47.91-61.41-86.09-70.51-75.89
Return on Invested Capital-94.97-78.03-48.25-55.22-30.78-49.12-100.76-82.35-61.05
Quick Ratio5.305.486.275.8318.896.062.474.698.37
Current Ratio5.305.486.275.8318.896.062.474.698.37

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-53.32-74.12-64.02-50.40-45.34-33.78-16.23-23.76-34.52
Depreciation1.591.551.542.741.701.301.271.370.75
Other Funds (Non Cash)6.743.130.28-0.582.601.991.922.184.15
Funds from Operations-44.99-69.44-62.20-48.23-41.05-30.49-13.04-20.22-29.61
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.417.45-6.9215.01-0.83-2.59-2.260.21-1.45
Cash from Operating Activities-43.58-61.99-69.12-33.22-41.89-33.08-15.30-20.01-31.06
Capital Expenditures-0.29-0.08-0.07-4.21-1.64-0.19-0.20-0.08-0.59
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.010.010.010.010.180.050.020.05-
Purchase or Sale of Investments49.26-4.9917.29-15.9348.71-91.427.084.9537.77
Purchase of Investments-41.42-93.44-69.10-106.98-42.12-126.51-21.07-40.65-40.30
Sale Or Maturity of Investments90.6888.4686.3991.0590.8335.0828.1545.6078.06
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities48.98-5.0517.23-20.1347.24-91.576.904.9237.17
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.9166.5540.3666.625.52110.036.459.340.43
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.9166.5540.3666.625.52110.036.459.340.43
Proceedsfrom Stock Options0.8766.4240.2666.525.47109.956.449.320.38
Issuance or Reduction of Debt, Net-0.54-0.54-0.50-0.39-0.070.009.70-8.00-4.67
Change in Long Term Debt-0.54-0.54-0.50-0.39-0.070.009.70-8.00-4.67
Issuance of Long Term Debt0.000.000.000.000.000.0018.780.00-
Reduction of Long Term Debt-0.54-0.54-0.50-0.39-0.070.00-9.08-8.00-4.67
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.3766.0139.8666.235.45110.0316.141.34-4.24
Net Change in Cash5.78-1.03-12.0212.8810.81-14.627.74-13.751.87
Free Cash Flow-43.86-62.06-69.18-37.44-43.53-33.27-15.50-20.09-31.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments48.7557.4266.5178.6990.2080.35
Short Term Receivables0.580.430.480.871.040.50
Inventories0.000.000.000.000.000.00
Other Current Assets0.820.520.590.681.776.65
Total Current Assets50.1658.3667.5880.2493.0187.49
Net Property, Plant & Equipment7.919.7810.1210.3810.7811.10
Total Investments and Advances1.501.501.802.232.712.88
Deferred Tax Assets---1.16--
Other Assets0.240.190.150.150.150.07
Total Assets59.8169.8379.6594.16106.65101.53
Short Term Debt Incl. Current Port. of LT Debt1.371.461.491.471.431.33
Accounts Payable3.903.242.753.894.063.88
Other Current Liabilities11.196.697.469.7910.1910.32
Total Current Liabilities16.4611.4011.7015.1515.6815.53
Long Term Debt9.559.8410.2110.5710.9311.35
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.16--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities26.0121.2321.9126.8826.6126.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity33.9848.7957.9367.4880.2374.84
Total Shareholders Equity33.9848.7957.9367.4880.2374.84
Accumulated Minority Interest-0.19-0.19-0.19-0.19-0.19-0.19
Total Equity33.7948.5957.7467.2980.0474.66
Total Liabilities & Stockholders Equity59.8169.8379.6594.16106.65101.53
Book Value Per Share13.5319.9023.6327.5332.7532.24
Tangible Book Value Per Share13.5319.9023.6327.5332.7532.24
Full-Time Employees---58--
Price to Book Ratio0.561.201.321.140.886.29
Return on Assets-64.07-70.97-79.17-77.12-75.78-64.24
Return on Equity-93.37-98.37-105.32-107.81-103.22-85.18
Return on Invested Capital-41.95-17.59-15.83-17.89-28.24-22.66
Quick Ratio3.055.125.785.305.935.63
Current Ratio3.055.125.785.305.935.63

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.26-10.31-10.79-13.96-25.75-19.53
Depreciation0.400.410.390.390.390.39
Other Funds (Non Cash)3.900.951.050.830.800.85
Funds from Operations-13.95-8.95-9.35-12.74-24.56-18.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.44-0.40-3.170.544.094.40
Cash from Operating Activities-9.51-9.35-12.52-12.20-20.48-13.89
Capital Expenditures-0.04-0.07-0.14-0.03-0.04-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.000.00
Purchase or Sale of Investments5.7715.3911.6316.46-20.343.31
Purchase of Investments-14.73-7.98-5.87-12.85-39.34-18.16
Sale Or Maturity of Investments20.5023.3717.5029.3119.0021.46
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.7215.3211.4916.44-20.383.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.890.020.000.0129.7518.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.890.020.000.0129.7518.03
Proceedsfrom Stock Options0.890.000.00-0.0229.7517.93
Issuance or Reduction of Debt, Net-0.11-0.14-0.14-0.14-0.14-0.13
Change in Long Term Debt-0.11-0.14-0.14-0.14-0.14-0.13
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.11-0.14-0.14-0.14-0.14-0.13
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.77-0.13-0.14-0.1329.6217.90
Net Change in Cash-3.015.84-1.174.12-11.247.30
Free Cash Flow-9.56-9.42-12.65-12.23-20.51-13.90

Revenue breakdown

Total Biological Products, (No Diagnostic Substances) revenue2024: 235.00K 2025: 190.00K
United States2024: 235.00K 2025: 190.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.3M-91.11K
2026-10-1510.96%0.3M2.3M80.19K
2026-09-3013.75%0.3M2.3M80.99K
2026-09-1511.38%0.3M2.3M32.27K
2026-08-319.90%0.2M2.3M36.46K
2026-08-1410.07%0.2M2.3M50.86K
2026-07-3110.18%0.2M2.4M68.14K
2026-07-158.67%0.2M2.4M68.69K
2026-06-3015.19%0.4M2.4M63.77K
2026-06-1519.38%0.5M2.4M55.80K
2026-05-2921.14%0.5M2.4M52.99K
2026-05-1522.37%0.5M2.4M44.47K
2026-04-3020.75%0.5M2.4M33.13K
2026-04-1520.79%0.5M2.4M41.00K
2026-03-3120.52%0.5M2.4M43.32K
2026-03-1319.84%0.5M2.4M49.30K
2026-02-2719.67%0.5M2.4M52.22K
2026-02-1320.81%0.5M2.4M58.45K
2026-01-3021.39%0.5M2.4M64.93K
2026-01-1522.33%0.5M2.4M76.40K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-06SEC
2026-11-06424B5SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-04SCHEDULE 13G/ASEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-013Initial statement of beneficial ownership of securities2026-10-01SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-11DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-08-31PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-06SCHEDULE 13G/ASEC
2026-07-318-KCurrent report2026-07-30SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-088-KCurrent report2026-06-03SEC
2026-06-05SCHEDULE 13G/ASEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0549.63K100
2026-040000
2026-030000
2026-02006.27K3
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FEDERATED HERMES, INC.8.68%
VANGUARD CAPITAL MANAGEMENT LLC3.88%
Kalehua Capital Management LLC3.65%
GSA CAPITAL PARTNERS LLP3.52%
AQR CAPITAL MANAGEMENT LLC2.66%
BlackRock, Inc.1.86%
FMR LLC1.82%
JANE STREET GROUP, LLC1.76%
MORGAN STANLEY1.37%
TWO SIGMA INVESTMENTS, LP1.27%

Funds

Fund% owned
Strategic Income Opportunities Fund4.53%
Federated Hermes Kaufmann Fund4.45%
Fidelity Growth Company Fund4.30%
Federated Hermes Kaufmann Small Cap Fund4.14%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
Select Biotechnology Portfolio1.79%
Income Fund1.72%
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Small Cap Index Fund0.95%
Fidelity Extended Market Index Fund0.56%

OakChart. ATYR. Cached 15 minutes.